Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer

We designed a single-arm, open label phase II study to determine the efficacy and toxicity of the combination of pazopanib with CapeOx (capecitabine and oxaliplatin) in metastatic /recurrent advanced gastric cancer (AGC) patients. Previously untreated AGC patients received capecitabine (850 mg/m(2)...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Seung Tae, Lee, Jeeyun, Lee, Su Jin, Park, Se Hoon, Jung, Sin-Ho, Park, Young Suk, Lim, Ho Yeong, Kang, Won Ki, Park, Joon Oh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029686/
https://www.ncbi.nlm.nih.gov/pubmed/27003363
http://dx.doi.org/10.18632/oncotarget.8175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029686/
https://www.ncbi.nlm.nih.gov/pubmed/27003363
http://dx.doi.org/10.18632/oncotarget.8175

Ejemplares similares